Literature DB >> 20477391

Tau as a biomarker of neurodegenerative diseases.

Susanna Schraen-Maschke1, Nicolas Sergeant, Claire-Marie Dhaenens, Stéphanie Bombois, Vincent Deramecourt, Marie-Laure Caillet-Boudin, Florence Pasquier, Claude-Alain Maurage, Bernard Sablonnière, Eugeen Vanmechelen, Luc Buée.   

Abstract

The microtubule-associated protein Tau is mainly expressed in neurons of the CNS and is crucial in axonal maintenance and axonal transport. The rationale for Tau as a biomarker of neurodegenerative diseases is that it is a major component of abnormal intraneuronal aggregates observed in numerous tauopathies, including Alzheimer's disease. The molecular diversity of Tau is very useful when analyzing it in the brain or in the peripheral fluids. Immunohistochemical and biochemical characterization of Tau aggregates in the brain allows the postmortem classification and differential diagnosis of tauopathies. As peripheral biomarkers of Alzheimer's disease in the cerebrospinal fluid, Tau proteins are now validated for diagnosis and predictive purposes. For the future, the detailed characterization of Tau in the brain and in peripheral fluids will lead to novel promising biomarkers for differential diagnosis of dementia and monitoring of therapeutics.

Entities:  

Year:  2008        PMID: 20477391      PMCID: PMC2993973          DOI: 10.2217/17520363.2.4.363

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  178 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Proteasomal degradation of tau protein.

Authors:  Della C David; Robert Layfield; Louise Serpell; Yolanda Narain; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

3.  Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome.

Authors:  Andrew J Sharp; Sierra Hansen; Rebecca R Selzer; Ze Cheng; Regina Regan; Jane A Hurst; Helen Stewart; Sue M Price; Edward Blair; Raoul C Hennekam; Carrie A Fitzpatrick; Rick Segraves; Todd A Richmond; Cheryl Guiver; Donna G Albertson; Daniel Pinkel; Peggy S Eis; Stuart Schwartz; Samantha J L Knight; Evan E Eichler
Journal:  Nat Genet       Date:  2006-08-13       Impact factor: 38.330

4.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.

Authors:  Bin Zhang; Arpita Maiti; Sharon Shively; Fara Lakhani; Gaye McDonald-Jones; Jennifer Bruce; Edward B Lee; Sharon X Xie; Sonali Joyce; Chi Li; Philip M Toleikis; Virginia M-Y Lee; John Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

5.  Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.

Authors:  Tetsuaki Arai; Kenji Ikeda; Haruhiko Akiyama; Kuniaki Tsuchiya; Shuji Iritani; Koichi Ishiguro; Saburo Yagishita; Tatsuro Oda; Toshinari Odawara; Eizo Iseki
Journal:  Acta Neuropathol       Date:  2003-02-08       Impact factor: 17.088

6.  A 17q21.31 microdeletion encompassing the MAPT gene in a mentally impaired patient.

Authors:  M C Varela; A C V Krepischi-Santos; J A Paz; J Knijnenburg; K Szuhai; C Rosenberg; C P Koiffmann
Journal:  Cytogenet Genome Res       Date:  2006       Impact factor: 1.636

7.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

8.  Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Authors:  F J Jiménez-Jiménez; A Hernánz; S Medina-Acebrón; F de Bustos; J M Zurdo; H Alonso; I Puertas; B Barcenilla; Y Sayed; F Cabrera-Valdivia
Journal:  Acta Neurol Scand       Date:  2005-02       Impact factor: 3.209

9.  Interaction of tau protein with the dynactin complex.

Authors:  Enrico Magnani; Juan Fan; Laura Gasparini; Matthew Golding; Meredith Williams; Giampietro Schiavo; Michel Goedert; Linda A Amos; Maria Grazia Spillantini
Journal:  EMBO J       Date:  2007-10-11       Impact factor: 11.598

10.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Authors:  K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

View more
  41 in total

1.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Authors:  Laetitia Troquier; Raphaelle Caillierez; Sylvie Burnouf; Francisco J Fernandez-Gomez; Marie-Eve Grosjean; Nadege Zommer; Nicolas Sergeant; Susanna Schraen-Maschke; David Blum; Luc Buee
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

Review 2.  Progress update: fluid and imaging biomarkers in Alzheimer's disease.

Authors:  Courtney L Sutphen; Anne M Fagan; David M Holtzman
Journal:  Biol Psychiatry       Date:  2013-09-05       Impact factor: 13.382

3.  Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.

Authors:  Saffire H Krance; Hugo Cogo-Moreira; Jennifer S Rabin; Sandra E Black; Walter Swardfager
Journal:  J Neurosci       Date:  2019-07-26       Impact factor: 6.167

4.  Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Authors:  Hideyuki Takahashi; Zoe A Klein; Sarah M Bhagat; Adam C Kaufman; Mikhail A Kostylev; Tsuneya Ikezu; Stephen M Strittmatter
Journal:  Acta Neuropathol       Date:  2017-01-09       Impact factor: 17.088

5.  Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes.

Authors:  Matthew P Pase; Alexa S Beiser; Jayandra J Himali; Claudia L Satizabal; Hugo J Aparicio; Charles DeCarli; Geneviève Chêne; Carole Dufouil; Sudha Seshadri
Journal:  JAMA Neurol       Date:  2019-05-01       Impact factor: 18.302

6.  Association of Plasma Neurofilament Light with Postoperative Delirium.

Authors:  Tamara G Fong; Sarinnapha M Vasunilashorn; Edward R Marcantonio; Sharon K Inouye; Long Ngo; Towia A Libermann; Simon T Dillon; Eva M Schmitt; Alvaro Pascual-Leone; Steven E Arnold; Richard N Jones
Journal:  Ann Neurol       Date:  2020-09-15       Impact factor: 10.422

7.  Identification and Characterization of DNA Aptamers Specific for Phosphorylation Epitopes of Tau Protein.

Authors:  I-Ting Teng; Xiaowei Li; Hamad Ahmad Yadikar; Zhihui Yang; Long Li; Yifan Lyu; Xiaoshu Pan; Kevin K Wang; Weihong Tan
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

8.  cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.

Authors:  Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang
Journal:  Int J Alzheimers Dis       Date:  2010-09-19

Review 9.  Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.

Authors:  Yongyao Fu; Deming Zhao; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2014-06-25       Impact factor: 3.444

10.  miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo.

Authors:  Pascal Y Smith; Julia Hernandez-Rapp; Francis Jolivette; Cynthia Lecours; Kanchan Bisht; Claudia Goupil; Veronique Dorval; Sepideh Parsi; Françoise Morin; Emmanuel Planel; David A Bennett; Francisco-Jose Fernandez-Gomez; Nicolas Sergeant; Luc Buée; Marie-Ève Tremblay; Frédéric Calon; Sébastien S Hébert
Journal:  Hum Mol Genet       Date:  2015-09-11       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.